



ORAL VANCOMYCIN: VIALS VS CAPSULES

M. Marín, A. Rodríguez, A. Echeverría, J. Gorricho, A. Gil, O. Goñi, L. Sanz, J. Garjon, J. Fernández Pharmacy and Services Sub-Directorate. Navarre Health Service.

 Contact data: Marta Marin (mmarinma@navarra.es) (Spain)



BACKGROUND AND IMPORTANCE

Current CDI guidance recommends, for a first episode without relapse risk factors, oral vancomycin 125 mg every 6 hours for 10 days. In Spain, there is no commercial oral product, so treatment relies on reconstituted vancomycin vials or compounded vancomycin capsules.

Until 2023, our community used only vials; from then on, capsules were prioritized.

AIM AND OBJETIVES

- ✓ Hypothesis: Manipulating vials for oral vancomycin may reduce CDI resolution.
- ✓ Objective: Compare relapse rates by pharmaceutical form (vials vs capsules) to assess effectiveness.


MATERIALS AND METHODS

Retrospective observational study of adults with CDI receiving oral vancomycin (01/07/2023–01/07/2025).

Collected data: age; vancomycin form; 3-month relapse; next treatment lines; leukocyte, albumin, creatinine; and antibiotics given during CDI therapy.

ATLAS score estimated relapse risk. Scores of 3 or more were associated with 3.6% mortality and 89.5% cure.

RESULTS



100% cases resolved



Second-line treatment

- 103 Fidaxomicine
- 4 switched from vancomycin vials to capsule

CONCLUSION AND RELEVANCE

- ✓ Patients treated with capsules had a higher risk of relapse but also a higher cure rate than patients treated with oral reconstituted vancomycin vials.
- ✓ These differences may reflect the small sample size.
- ✓ Handling vials could itself

